OPK earnings call for the period ending June 30, 2019.
News & Analysis: Opko Health
A decision by a key Medicare contractor to pay for OPKO's prostate-cancer test provided a nice boost to the stock.
Disappointing Q1 results weighed on the healthcare stock.
Traders didn't like the company's fourth-quarter results. Should you?
A convertible senior note offering and related issuing of new shares caused the healthcare stock to plunge.
Better-than-expected Q3 results give the beaten-down healthcare stock a spark.
Investors are betting that a recent tumble will provide a good buy opportunity.
Investors remained very worried about the SEC's allegations of fraud.
SEC "pump-and-dump" charges against the company and its CEO led to a major plunge in Opko's share price.
Opko's turnaround is starting to gain momentum.
Investors are feeling more comfortable with the potential of the company's drugs and diagnostic tests.